AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31504624 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths and Difficulties Questionnaire in Norwegian Sign Language (SDQ-NSL)
Number of subjects: 49
Study 31504624 — intervention group
Group type: COMPARATOR
Intervention: Strengths and Difficulties Questionnaire in written Norwegian (SDQ-NOR)
Number of subjects: 49
Study 31154315 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping intervention for recurrent miscarriage (details not specified)
Number of subjects: 14
Study 31154315 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 14
Study 28886907 — intervention group
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Number of subjects: 14215
Study 28886907 — intervention group
Group type: COMPARATOR
Intervention: qHPV vaccine (control)
Number of subjects: 14215
Study 26355492 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 200
Study 26355492 — intervention group
Group type: COMPARATOR
Intervention: PRO-Breathe
Number of subjects: 200
Study 26355492 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel size 1.5
Number of subjects: 200
Study 26355492 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel size 2
Number of subjects: 200
Study 26355492 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel size 2.5
Number of subjects: 200
Study 26355492 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel size 3
Number of subjects: 200
Study 24108790 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibrated RQ estimates using 4-day food record (4DFR) data
Number of subjects: 0
Study 24108790 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibrated RQ estimates using food-frequency data
Number of subjects: 0
Study 21420586 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac 0.1% applied 2 hours before PRK
Number of subjects: 70
Study 21420586 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied 2 hours before PRK
Number of subjects: 70
Study 21420586 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac 0.1% applied every 6 hours for 2 days postoperatively
Number of subjects: 70
Study 19208729 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-sweetened beverages
Number of subjects: 17
Study 19208729 — intervention group
Group type: COMPARATOR
Intervention: Glucose-sweetened beverages
Number of subjects: 17
Study 17306936 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter interfraction interval (IFI) of 4.5-5.0 hours (n = 52)
Number of subjects: 103
Study 17306936 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer interfraction interval (IFI) of 5.5-6.0 hours (n = 51)
Number of subjects: 103
Study 17306936 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter IFI
Number of subjects: 103
Study 17306936 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer IFI
Number of subjects: 103
Study 17306936 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (n = 103)
Number of subjects: 103
Study 15330012 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulative therapy (SMT)
Number of subjects: 0
Study 15330012 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11166750 — intervention group
Group type: EXPERIMENTAL
Intervention: Mantoux test
Number of subjects: 300
Study 9560871 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM) group intervention
Number of subjects: 40
Study 9560871 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 40
Study 7751567 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR technique for detection of Shigella and EIEC
Number of subjects: 119
Study 7751567 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy with PCR detection after 3 days
Number of subjects: 119
Study 7751567 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy with PCR detection after 7 days
Number of subjects: 119
Study 7751567 — intervention group
Group type: COMPARATOR
Intervention: Standard microbiological methods
Number of subjects: 119
Study 2839019 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril (2.5 to 40 mg/day)
Number of subjects: 253
Study 2839019 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 253
Study 31647001 — intervention group
Group type: EXPERIMENTAL
Intervention: Teach-back communication strategy
Number of subjects: 70
Study 31647001 — intervention group
Group type: COMPARATOR
Intervention: Standard medical consultation (control)
Number of subjects: 70
Study 28877891 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free mass
Number of subjects: 191
Study 28877891 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting prospective food consumption ratings and RMR
Number of subjects: 191
Study 28877891 — intervention group
Group type: EXPERIMENTAL
Intervention: RMR
Number of subjects: 191
Study 25740979 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 492
Study 25740979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 492
Study 23621808 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate-coated pins in the tibial shaft
Number of subjects: 20
Study 23621808 — intervention group
Group type: COMPARATOR
Intervention: Uncoated pins in the tibial shaft
Number of subjects: 20
Study 23621808 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate-coated pins in the metaphysis
Number of subjects: 20
Study 23621808 — intervention group
Group type: COMPARATOR
Intervention: HA-coated pins in the metaphysis
Number of subjects: 20
Study 20176450 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐amphetamine (20mg)
Number of subjects: 34
Study 20176450 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressful task (public speech)
Number of subjects: 34
Study 20176450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 20176450 — intervention group
Group type: COMPARATOR
Intervention: Non-stressful control task
Number of subjects: 34
Study 18209133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implant activated (on)
Number of subjects: 41
Study 18209133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implant deactivated (off)
Number of subjects: 41
Study 18209133 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal hearing)
Number of subjects: 41
Study 16545724 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily filgrastim at 400 microg/m(2)/d
Number of subjects: 72
Study 16545724 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily filgrastim at 400 microg/m(2)/d
Number of subjects: 72
Study 16545724 — intervention group
Group type: COMPARATOR
Intervention: Both groups (O and T)
Number of subjects: 72
Study 14615662 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) prophylaxis
Number of subjects: 250
Study 14615662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 14615662 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) prophylaxis (low viral load)
Number of subjects: 250
Study 14615662 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) prophylaxis (high viral load)
Number of subjects: 250
Study 11049884 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with ondansetron
Number of subjects: 180
Study 11049884 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 180
Study 11049884 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane alone
Number of subjects: 180
Study 8659426 — intervention group
Group type: EXPERIMENTAL
Intervention: CAST with 150 ml of contrast material
Number of subjects: 183
Study 8659426 — intervention group
Group type: EXPERIMENTAL
Intervention: CAST with 125 ml of contrast material
Number of subjects: 183
Study 8659426 — intervention group
Group type: EXPERIMENTAL
Intervention: CAST with 100 ml of contrast material
Number of subjects: 183
Study 8659426 — intervention group
Group type: COMPARATOR
Intervention: Control with 150 ml of contrast material
Number of subjects: 183
Study 8659426 — intervention group
Group type: COMPARATOR
Intervention: Control with 100 ml of contrast material
Number of subjects: 183
Study 1389714 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 8
Study 1389714 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine plus isosorbide mononitrate
Number of subjects: 8
Study 1389714 — intervention group
Group type: COMPARATOR
Intervention: Control (no vasodilator)
Number of subjects: 8
Study 3908884 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestriol 3 mg daily for 3 months
Number of subjects: 34
Study 3908884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 30683710 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT mobile app for anxiety
Number of subjects: 145
Study 30683710 — intervention group
Group type: COMPARATOR
Intervention: Health education program (control)
Number of subjects: 145
Study 29384318 — intervention group
Group type: EXPERIMENTAL
Intervention: High eating frequency (HEF) meals at 08:00, 10:00, 12:00, 15:00, 18:00 and 20:00 h
Number of subjects: 70
Study 29384318 — intervention group
Group type: COMPARATOR
Intervention: Normal eating frequency (NEF) meals at 08:00, 12:00 and 18:00 h
Number of subjects: 70
Study 29384318 — intervention group
Group type: EXPERIMENTAL
Intervention: High eating frequency (HEF)
Number of subjects: 70
Study 27061066 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline+Rotigotine
Number of subjects: 130
Study 27061066 — intervention group
Group type: COMPARATOR
Intervention: Selegiline+Placebo
Number of subjects: 130
Study 24625044 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training using the method of loci (MoL)
Number of subjects: 1401
Study 24625044 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MoL training)
Number of subjects: 1401
Study 22133660 — intervention group
Group type: EXPERIMENTAL
Intervention: AG200‐15
Number of subjects: 36
Study 20658006 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy (AsGaAl laser, 40mW power, 80J/cm² for 16 seconds at four selected points, one session)
Number of subjects: 50
Study 20658006 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 50
Study 17999404 — intervention group
Group type: EXPERIMENTAL
Intervention: RT and immediate goserelin
Number of subjects: 945
Study 17999404 — intervention group
Group type: COMPARATOR
Intervention: RT alone followed by goserelin at recurrence
Number of subjects: 945
Study 17999404 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI > or =25 to <30
Number of subjects: 945
Study 17999404 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI > or =30
Number of subjects: 945
Study 17999404 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 945
Study 15071488 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril-Manidipine combination
Number of subjects: 80
Study 15071488 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan-Hydrochlorothiazide combination
Number of subjects: 80
Study 12479682 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug trials in mania, specific interventions not detailed
Number of subjects: 0
Study 12479682 — intervention group
Group type: COMPARATOR
Intervention: Various treatments, alone or in combination, specific interventions not detailed
Number of subjects: 0
Study 9619120 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 2 g/kg + Piperine 20 mg/kg in rats
Number of subjects: 0
Study 9619120 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 2 g + Piperine 20 mg in humans
Number of subjects: 0
Study 7862267 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate (1 mg/kg body weight)
Number of subjects: 160
Study 7862267 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate (2 mg/kg body weight)
Number of subjects: 160
Study 7862267 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate (3 mg/kg body weight)
Number of subjects: 160
Study 7862267 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate (4 mg/kg body weight)
Number of subjects: 160
Study 7862267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 2919758 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.3 mg kg‐1)
Number of subjects: 40
Study 2919758 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (4 mg kg‐1)
Number of subjects: 40
Study 2919758 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and Thiopental
Number of subjects: 40
Study 2919758 — intervention group
Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 40
Study 28653428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (10 mg daily for 3 weeks)
Number of subjects: 32
Study 28653428 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to DEX)
Number of subjects: 32
Study 27187320 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg E + 15 mg P (Group A)
Number of subjects: 84
Study 27187320 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E + 20 mg P (Group B)
Number of subjects: 84
Study 27187320 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E + 30 mg P (Group C)
Number of subjects: 84
Study 24730653 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Pain Self‐Management Program
Number of subjects: 0
Study 24730653 — intervention group
Group type: COMPARATOR
Intervention: Tailored Physical Activity
Number of subjects: 0
Study 23715519 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (supplementation with 1,200 mg n‐3 LCPUFAs per day and instructions to reduce arachidonic acid (AA) intake)
Number of subjects: 208
Study 23715519 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 208
Study 23715519 — intervention group
Group type: COMPARATOR
Intervention: Control (habitual diet)
Number of subjects: 208
Study 21210111 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional staging + PET/CT
Number of subjects: 189
Study 21210111 — intervention group
Group type: COMPARATOR
Intervention: Conventional staging
Number of subjects: 189
Study 18502239 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing with discussion of values
Number of subjects: 20
Study 18502239 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing without discussion of values
Number of subjects: 20
Study 18502239 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (both groups)
Number of subjects: 20
Study 17158425 — intervention group
Group type: EXPERIMENTAL
Intervention: High iron supplementation
Number of subjects: 1657
Study 17158425 — intervention group
Group type: EXPERIMENTAL
Intervention: Low iron supplementation
Number of subjects: 1657
Study 17158425 — intervention group
Group type: COMPARATOR
Intervention: No added iron
Number of subjects: 1657
Study 17158425 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1657
Study 12660532 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 106
Study 12660532 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 106
Study 12660532 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 106
Study 12660532 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 106
Study 12660532 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 106
Study 10714846 — intervention group
Group type: EXPERIMENTAL
Intervention: pethidine 17.5 mg
Number of subjects: 45
Study 10714846 — intervention group
Group type: EXPERIMENTAL
Intervention: pentazocine 7.5 mg
Number of subjects: 45
Study 10714846 — intervention group
Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 45
Study 9175960 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine with fentanyl 1 microgram ml‐1
Number of subjects: 223
Study 9175960 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine with fentanyl 2 micrograms ml‐1
Number of subjects: 223
Study 9175960 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine with fentanyl 3 micrograms ml‐1
Number of subjects: 223
Study 9175960 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine with fentanyl 4 micrograms ml‐1
Number of subjects: 223
Study 9175960 — intervention group
Group type: COMPARATOR
Intervention: plain bupivacaine
Number of subjects: 223
Study 1313120 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion at a rate of 30 ng.kg‐1.min‐1 during cardiopulmonary bypass (CPB)
Number of subjects: 19
Study 1313120 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Control group)
Number of subjects: 19
Study 1313120 — intervention group
Group type: COMPARATOR
Intervention: Both groups (PGE1 and Control)
Number of subjects: 19
Study 3886308 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg 3-times daily)
Number of subjects: 36
Study 3886308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31353814 — intervention group
Group type: EXPERIMENTAL
Intervention: VOICE risk score (scores ≥5)
Number of subjects: 0
Study 31353814 — intervention group
Group type: EXPERIMENTAL
Intervention: VOICE risk score
Number of subjects: 0
Study 28419448 — intervention group
Group type: EXPERIMENTAL
Intervention: Match condition (tablet)
Number of subjects: 42
Study 28419448 — intervention group
Group type: COMPARATOR
Intervention: Mismatch condition (felt board)
Number of subjects: 42
Study 28419448 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Memory (WM) assessment
Number of subjects: 42
Study 28419448 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual match
Number of subjects: 42
Study 28419448 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive interference
Number of subjects: 42
Study 27022113 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus enhanced self-care
Number of subjects: 190
Study 27022113 — intervention group
Group type: COMPARATOR
Intervention: Enhanced self-care
Number of subjects: 190
Study 25006118 — intervention group
Group type: EXPERIMENTAL
Intervention: Newsletter (N)
Number of subjects: 22
Study 25006118 — intervention group
Group type: EXPERIMENTAL
Intervention: Newsletter and growth monitoring (N + GM)
Number of subjects: 22
Study 25006118 — intervention group
Group type: EXPERIMENTAL
Intervention: Newsletter and growth monitoring plus family-based behavioral counseling (N + GM + BC)
Number of subjects: 22
Study 22695973 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-leg spica cast
Number of subjects: 52
Study 22695973 — intervention group
Group type: COMPARATOR
Intervention: Double-leg spica cast
Number of subjects: 52
Study 20884164 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastatic lymph node ratio (LNR)
Number of subjects: 605
Study 20884164 — intervention group
Group type: EXPERIMENTAL
Intervention: LNR value of 0.60
Number of subjects: 605
Study 20884164 — intervention group
Group type: COMPARATOR
Intervention: Pre-operative radiotherapy
Number of subjects: 605
Study 19621648 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates breathing exercise method
Number of subjects: 0
Study 19621648 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 17166985 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management education program 'Living Well with COPD' with ongoing supervision by a case manager
Number of subjects: 191
Study 14738640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirena (levonorgestrel‐releasing intrauterine device) inserted after endometrial resection
Number of subjects: 95
Study 14738640 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further treatment after endometrial resection)
Number of subjects: 95
Study 10920832 — intervention group
Group type: EXPERIMENTAL
Intervention: APN interventions (standard care plus APN interventions based on Brooten's cost‐quality model)
Number of subjects: 210
Study 10920832 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 210
Study 9012304 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate in lipid emulsion (0.51 mg/kg)
Number of subjects: 100
Study 9012304 — intervention group
Group type: COMPARATOR
Intervention: Propofol in long chain triglyceride emulsion (3.04 mg/kg)
Number of subjects: 100
Study 1555871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 878
Study 1555871 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 878
Study 1555871 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 mg)
Number of subjects: 878
Study 3884690 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocortin butyl (FCB) 2 mg per day
Number of subjects: 235
Study 3884690 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocortin butyl (FCB) 4 mg per day
Number of subjects: 235
Study 3884690 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocortin butyl (FCB) 8 mg per day
Number of subjects: 235
Study 3884690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 30980471 — intervention group
Group type: EXPERIMENTAL
Intervention: Struts thickness ≤81 nm
Number of subjects: 52006
Study 30980471 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean number of connectors >2.5
Number of subjects: 52006
Study 30980471 — intervention group
Group type: EXPERIMENTAL
Intervention: Average number of crowns <7.5
Number of subjects: 52006
Study 31219949 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration-Controlled Dosing (CC) of EC-MPS
Number of subjects: 19
Study 31219949 — intervention group
Group type: COMPARATOR
Intervention: Fixed-Dosing (FD) of EC-MPS
Number of subjects: 19
Study 28724273 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Salbutamol (200 micrograms)
Number of subjects: 20
Study 25781214 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 14
Study 25781214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 23234408 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFA diet (29 caloric % SAFA)
Number of subjects: 15
Study 23234408 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA diet (25 caloric % PUFA)
Number of subjects: 15
Study 21240818 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-shifting training (30-min sessions, 3 sessions/week, 4 weeks)
Number of subjects: 63